Document is current
Any future updates will be listed below
-
Authors
Johannet, Paul https://orcid.org/0000-0002-9264-8327
Rousseau, Benoit https://orcid.org/0000-0002-1594-4827
Aghajanian, Carol
Foote, Michael B.
Diaz, Luis A. Jr. https://orcid.org/0000-0002-7079-8914
- License Information
-
More Information
Article History
Accepted: 17 June 2025
First Online: 10 July 2025
Competing interests
: B.R. has acted as a consultant and/or adviser for Neophore and Artios Pharma and is an inventor of a patent related to MMRd and immunotherapy. C.A. has received grants or contracts from Abbvie, Artios, AstraZeneca, Clovis and Genentech/Roche; has participated on a Data Safety Monitoring Board or Advisory Board for AstraZeneca, Merck and WIRB-Copernicus Group (WCG); and has served in a leadership or fiduciary role for the GOG Foundation and NRG Oncology. M.B.F. has acted as a consultant and/or adviser to Abbott Laboratories, Bristol Myers Squibb and Genzyme. L.A.D.J. is a member of the board of directors of Epitope and Quest Diagnostics and is a compensated consultant to Absci, Blackstone, Delfi, GSK, Innovatus Capital Partners, Seer and Neophore. L.A.D.J. is also an inventor of multiple licenced patents related to technology for circulating tumour DNA analyses and MMRd for diagnosis and therapy; some of these licences and relationships are associated with equity or royalty payments to the inventors. He holds equity in Absci, Delfi, Epitope, Neophore, Quest Diagnostics and Seer. He divested his equity in Personal Genome Diagnostics to LabCorp in February 2022 and divested his equity in Thrive Earlier Detection to Exact Biosciences in January 2021. His spouse holds equity in Amgen. The terms of all these arrangements are being managed by Memorial Sloan Kettering in accordance with their conflict-of-interest policy. P.J. declares no competing interests.
